FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rose Mougnutou

Research Profile

Geographic Areas

Cameroon

Procedures

Living Beings

HIV-1

Disorders

HIV Infections

Concepts & Ideas

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Christian Laurent; Anke Bourgeois; Eitel Mpoudi-Ngolé; Charles Kouanfack; L Ciaffi; N Nkoué; Rose Mougnutou; Alexandra Calmy; Sinata Koulla-Shiro; J Ducos; Eric Delaporte
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Alessandro Soria; Klaudia Porten; Jean-Calvin Fampou-Toundji; Laura Galli; Rose Mougnutou; Vincent Buard; Anfumbom Kfutwah; Aurelia Vessière; Dominique Rousset; Roger Teck; Alexandra Calmy; Laura Ciaffi; Adriano Lazzarin; Nicola Gianotti
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Christian Laurent; Anke Bourgeois; Eitel Mpoudi-Ngolé; Laura Ciaffi; Charles Kouanfack; Rose Mougnutou; Nathalie Nkoué; Alexandra Calmy; Sinata Koulla-Shiro; Eric Delaporte
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rose Mougnutou (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Christian Laurent; Anke Bourgeois; Eitel Mpoudi-Ngolé; Charles Kouanfack; L Ciaffi; N Nkoué; Rose Mougnutou; Alexandra Calmy; Sinata Koulla-Shiro; J Ducos; Eric Delaporte
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
HIV medicine 2010;11(1):85-9.
2009: Alessandro Soria; Klaudia Porten; Jean-Calvin Fampou-Toundji; Laura Galli; Rose Mougnutou; Vincent Buard; Anfumbom Kfutwah; Aurelia Vessière; Dominique Rousset; Roger Teck; Alexandra Calmy; Laura Ciaffi; Adriano Lazzarin; Nicola Gianotti
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Antiviral therapy 2009;14(3):339-47.
2008: Christian Laurent; Anke Bourgeois; Eitel Mpoudi-Ngolé; Laura Ciaffi; Charles Kouanfack; Rose Mougnutou; Nathalie Nkoué; Alexandra Calmy; Sinata Koulla-Shiro; Eric Delaporte
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
AIDS research and human retroviruses 2008;24(3):393-9.
2005: Anke Bourgeois; Christian Laurent; Rose Mougnutou; Nathalie Nkoué; Bernadette Lactuock; Laura Ciaffi; Florian Liegeois; Isabelle Andrieux-Meyer; Leopold Zekeng; Alexandra Calmy; Eitel Mpoudi-Ngolé; Eric Delaporte
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Antiviral therapy 2005;10(2):335-41.
2004: Christian Laurent; Charles Kouanfack; Sinata Koulla-Shiro; Nathalie Nkoué; Anke Bourgeois; Alexandra Calmy; Bernadette Lactuock; Viviane Nzeusseu; Rose Mougnutou; Gilles Peytavin; Florian Liegeois; Eric Nerrienet; Michèle Tardy; Martine Peeters; Isabelle Andrieux-Meyer; Leopold Zekeng; Michel D Kazatchkine; Eitel Mpoudi-Ngolé; Eric Delaporte
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Lancet 2004;364(9428):29-34.
2003: Laurence Vergne; Anke Bourgeois; Eitel Mpoudi-Ngole; Rose Mougnutou; Josephine Mbuagbaw; Florian Liegeois; Christian Laurent; Christelle Butel; Leopold Zekeng; Eric Delaporte; Martine Peeters
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage.
Virology 2003;310(2):254-66.
2002: Christian Laurent; Anke Bourgeois; Mame Awa Faye; Rose Mougnutou; Moussa Seydi; Mandoumbé Gueye; Florian Liegeois; Coumba Touré Kane; Christelle Butel; Josephine Mbuagbaw; Leopold Zekeng; Souleymane MBoup; Eitel Mpoudi-Ngolé; Martine Peeters; Eric Delaporte
No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.
The Journal of infectious diseases 2002;186(4):486-92.